We have some amazing news to share with our network today, following an announcement this morning from the Australian Government.
People living with HER2-low metastatic breast cancer will, from 1 September 2024, have access to the life-prolonging drug Enhertu (trastuzumab deruxtecan) through the Pharmaceutical Benefits Scheme.
This could transform treatment for around 1,700 people each year. The announcement also removes the financial burden of treatment as the cost – $10,000 to $15,000 every 3 weeks – will now be just $31.60 ($7.70 concession).
We have advocated strongly for Enhertu to be subsidised and are extremely grateful for the input we have had from members with metastatic breast cancer.
Thank you to everyone who has helped make today’s announcement possible. That includes BCNA member Sarah Lee, one of the many champions whose voice helped get Enhertu listed on the PBS. By sharing her story so publicly, she is demonstrating the importance of increased access to this life-extending treatment.
You can read our announcement on the website and we hope to see some good media coverage in the days ahead.
If you have questions about Enhertu, including if it is a treatment you may be eligible for, we encourage you to speak to your treating team.
